BTX-A for persistent myofascial TMD pain: interpreting a small clinical trial with negative results

Affiliations

Editorial

Donald R Nixdorf. Pain. 2011 Sep.

. 2011 Sep;152(9):1944-1945.

doi: 10.1016/j.pain.2011.05.020.

¹ Division of TMD & Orofacial Pain, University of Minnesota School of Dentistry, Minneapolis, MN 55455, USA.

No abstract available

Comment on

Efficacy of botulinum toxin type A for treatment of persistent myofascial TMD pain: a randomized, controlled, double-blind multicenter study.
Ernberg M, Hedenberg-Magnusson B, List T, Svensson P. Ernberg M, et al. Pain. 2011 Sep;152(9):1988-1996. doi: 10.1016/j.pain.2011.03.036. Epub 2011 Apr 22. Pain. 2011. PMID: 21514731 Clinical Trial.

1. Ernberg M, Hedenberg-Magnusson B, List T, Svensson P. Efficacy of botulinum toxin type-A for treatment of persistent myofascial TMD pain: A randomized, controlled, double-blind multicenter study. Pain. 2011;152:1988-1996.
1. Fricton JR, Ouyang W, Nixdorf DR, Schiffman EL, Velly AM, Look JO. Critical appraisal of methods used in randomized controlled trials of treatments for temporomandibular disorders. J Orofac Pain. 2010;24:139-151.
1. Nixdorf DR, Heo G, Major PW. Randomized controlled trial of botulinum toxin A for chronic myogenous orofacial pain. Pain. 2002;99:465-473.
1. Kurtoglu C, Gur OH, Kurkcu M, Sertdemir Y, Guler-Uysal F, Uysal H. Effect of botulinum toxin-A in myofascial pain patients with or without functional disc displacement. J Oral Maxillofac Surg. 2008;66:1644-1651.
1. von Lindern JJ, Niederhagen B, Bergé S, Appel T. Type A botulinum toxin in the treatment of chronic gacial pain associated with masticatory hyperactivity. J Oral Maxillofac Surg. 2003;61:774-778.